Sun Pharma to acquire Concert Pharmaceuticals

20 Jan 2023 Evaluate

Sun Pharmaceutical Industries has inked a pact to acquire US-based Concert Pharmaceuticals in a $576 million (around Rs 4,688 crore) deal. The companies have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8 per share of common stock in cash.

The upfront payment of $8 per share of common stock in cash represents a premium of around 33 per cent to Concert’s 30-day volume weighted average price as of January 18, 2023. Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share of common stock in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods. Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.


Sun Pharma Inds. Share Price

1804.95 -13.65 (-0.75%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×